Design and rationale of the eLym™ System for Decompensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF).
Jan Biegus, JoAnn Lindenfeld, G Michael Felker...
https://pubmed.ncbi.nlm.nih.gov/39716986/Actively Recruiting
Led by WhiteSwell, Limited · Updated on 2026-01-07
70
Participants Needed
11
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and performance of the WhiteSwell eLym System for treating fluid overload or congestion in adults hospitalized with Acute Decompensated Heart Failure ADHF. This feasibility study focuses on assessing both acute and chronic device safety, as well as the technical success and patient treatment outcomes related to this device. The WhiteSwell eLym System is a device designed to reduce congestion by creating a low-pressure zone at the thoracic duct outflow, which helps move fluid from the lymphatic system back into the bloodstream. The device consists of a catheter and sheath used with a console and is temporarily placed for up to 60 hours via the left internal jugular vein while patients continue receiving intravenous diuretics. This treatment occurs during hospitalization, with the device placed in a heart catheterization laboratory. Participants will be monitored during their hospital stay and followed up at 30, 60, 90, and 180 days after discharge. Researchers will assess safety by tracking serious adverse events related to the device and treatment, technical success of device placement and removal, as well as changes in body weight, fluid levels, kidney function, lung water, and heart failure therapy needs. Additionally, quality of life and biomarker levels will be evaluated to understand long-term outcomes, including the time to rehospitalization for heart failure.
CONDITIONS
The Safety and Feasibility of the eLym™ System
S
Sergio Shkurovich
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
WhiteSwell, Limited
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 hours
Participants have the WhiteSwell eLym System temporarily placed via left internal jugular access to create a low-pressure zone at the Thoracic Duct Outflow, facilitating fluid movement to reduce congestion from Acute Decompensated Heart Failure.
Device placement and therapy duration occur during hospitalization
Duration - Up to 180 days post therapy
Participants are monitored after device removal to assess safety, kidney function, heart failure symptoms, and quality of life.
Follow-up visits at hospital discharge, 30, 90, and 180 days after hospital discharge
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jan Biegus, JoAnn Lindenfeld, G Michael Felker...
https://pubmed.ncbi.nlm.nih.gov/39716986/WhiteSwell, Limited
Lead Sponsor